See every side of every news story
Published loading...Updated

ABVC BioPharma Anticipates $7M in Licensing Income, Advances Botanical Drug Pipeline

Summary by citybuzz.co
Biopharmaceutical company ABVC BioPharma is poised to generate $7 million in cash licensing income during 2025, stemming from global licensing agreements signed in 2023 for drug candidates targeting major depressive disorder (MDD) and attention-deficit/hyperactivity disorder (ADHD). The company’s strategic positioning comes amid robust market growth projections. The global MDD market is expected to expand from $11.51 billion in 2022 to $14.96 bi…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

All
Left
Center
Right
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

citybuzz.co broke the news in on Thursday, February 20, 2025.
Sources are mostly out of (0)